KENGREAL
Drug
Chiesi USA, Inc.
Total Payments
$4.3M
Transactions
28,123
Doctors
9,915
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $786,683 | 1,734 | 1,130 |
| 2023 | $770,733 | 1,847 | 1,227 |
| 2022 | $369,221 | 4,925 | 3,038 |
| 2021 | $284,131 | 4,693 | 2,520 |
| 2020 | $105,766 | 627 | 416 |
| 2019 | $566,973 | 4,464 | 1,905 |
| 2018 | $634,864 | 4,425 | 1,936 |
| 2017 | $782,658 | 5,408 | 2,351 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.2M | 506 | 27.3% |
| Grant | $766,512 | 9 | 17.8% |
| Food and Beverage | $662,093 | 24,309 | 15.4% |
| Consulting Fee | $386,098 | 90 | 9.0% |
| Unspecified | $375,220 | 138 | 8.7% |
| Honoraria | $351,763 | 195 | 8.2% |
| Space rental or facility fees (teaching hospital only) | $303,792 | 106 | 7.1% |
| Travel and Lodging | $213,968 | 897 | 5.0% |
| Charitable Contribution | $27,500 | 4 | 0.6% |
| Education | $22,344 | 1,616 | 0.5% |
| Gift | $18,482 | 253 | 0.4% |
Payments by Type
General
$3.9M
27,985 transactions
Research
$375,220
138 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Pro00038725 | Chiesi USA, Inc. | $241,925 | 0 |
| MDCO-CAN-15-01 | CHIESI USA, INC. | $19,892 | 3 |
| MDCO-CAN-15-01 | Chiesi USA, Inc. | $9,075 | 1 |
| Open label study to assess the efficacy, safety, and dosing of Clevidipine in pediatric patients undergoing surgery PIONEER | The Medicines Company | $4,160 | 0 |
Top Doctors Receiving Payments for KENGREAL — Page 397
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Internal Medicine | Cary, NC | $10.44 | 1 |
| , M.D | Cardiovascular Disease | Lubbock, TX | $10.41 | 1 |
| , MD | Cardiovascular Disease | Lafayette, LA | $10.33 | 1 |
| , M.D | Internal Medicine | San Francisco, CA | $10.33 | 1 |
| , D.O | Cardiovascular Disease | Denver, CO | $10.33 | 1 |
| , D.O, | Anesthesiology | Albany, NY | $9.32 | 1 |
| , DO | Infectious Disease | Greenville, NC | $7.17 | 1 |
| , MD | Infectious Disease | Jackson, MS | $7.17 | 1 |
| , M.D | Interventional Cardiology | Omaha, NE | $6.92 | 1 |
| , M.D | Anesthesiology | Columbus, OH | $3.27 | 2 |
| , M.D | Cardiovascular Disease | Council Bluffs, IA | $1.44 | 3 |
| , D.O | Family Medicine | Corpus Christi, TX | $0.88 | 2 |
| , D.O | Internal Medicine | Corpus Christi, TX | $0.88 | 2 |
| , MD | Internal Medicine | San Antonio, TX | $0.66 | 1 |
| , MD | Pulmonary Disease | Tupelo, MS | $0.57 | 1 |
| Constantine Athanasuleas | Vascular Surgery | Birmingham, AL | $0.43 | 1 |
Ad
Manufacturing Companies
- Chiesi USA, Inc. $3.9M
- CHIESI USA, INC. $412,298
- The Medicines Company $4,189
Product Information
- Type Drug
- Total Payments $4.3M
- Total Doctors 9,915
- Transactions 28,123
About KENGREAL
KENGREAL is a drug associated with $4.3M in payments to 9,915 healthcare providers, recorded across 28,123 transactions in the CMS Open Payments database. The primary manufacturer is Chiesi USA, Inc..
Payment data is available from 2017 to 2024. In 2024, $786,683 was paid across 1,734 transactions to 1,130 doctors.
The most common payment nature for KENGREAL is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.2M, 27.3% of total).
KENGREAL is associated with 4 research studies, including "Pro00038725" ($241,925).